Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Core Viewpoint - Sight Sciences, Inc. has achieved a significant legal victory in its patent infringement case against Alcon, with the court upholding the jury's verdict of willful infringement and awarding substantial monetary damages [1][2]. Legal Outcome - The U.S. District Court for the District of Delaware confirmed the jury's verdict that Alcon willfully infringed three patents held by Sight Sciences, resulting in a monetary award of $34 million for past infringement, along with ongoing royalties of 10% of Hydrus revenue until November 10, 2028 [2][6]. - The final judgment is pending and will include supplemental damages and interest, with the possibility of an appeal by Alcon [2][6]. Financial Implications - The past monetary damages consist of $5.5 million in lost profits and $28.5 million in royalty damages related to Hydrus sales from its launch until the jury verdict [6]. - The company anticipates recording a $5.4 million success fee to operating expenses, which will be excluded from non-GAAP adjusted operating expenses [4]. Company Overview - Sight Sciences focuses on developing innovative eyecare technologies aimed at transforming patient care, particularly in the field of glaucoma treatment [5]. - The company's product offerings include the OMNI® Surgical System and TearCare® System, which utilize minimally invasive techniques to address prevalent eye diseases [5]. Intellectual Property Strategy - The company emphasizes the importance of safeguarding its intellectual property portfolio, which includes microinvasive glaucoma implants and canaloplasty devices, to support ongoing innovation and investment in new treatment solutions [4].